Potential Research Participants
  • For more information about a specific study, please call the contact person listed for that study.
  • For general questions about participating in research studies at OHSU you may contact the Clinical Research Navigator at (503) 346-3540.
  • If you have any questions regarding your rights as a research subject, you may contact the OHSU Research Integrity Office at (503) 494-7887.

Return to Search

Study Opportunities (315 Results)
1) Oregon Colorectal Cancer Registry
2) Oregon Pancreas Tissue Registry
3) [STEM CELLS] Histocompatible human pluripotent cells
4) Quantitative Dynamic Contrast-Enhanced Breast MRI
5) [UMiami – MOU] TrialNet Natural History Study of the Development of Type 1 Diabetes
6) Preclinical studies on endometrial xenografts
7) Oregon Liver Tumor Registry
8) Transepithelial Potential Difference Measurements in Patients with Unusual Variants of Cystic Fibrosis
9) VAPORHCS/OHSU J:Optimization of Cochlear Implants and Hearing Aids (VA#3744)
10) [Wake Forest IRB - IREx] I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
11) Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
12) Harold Schnitzer Diabetes Health Center Research Department Contact and Health Information Repository
13) Objective grading of intraocular inflammation in uveitis using optical coherence tomography
14) Relationship between HLA B27, disease status and the human microbiome
15) Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
16) A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
17) Oregon Index of Endocrine Neoplasias (ORION)
18) The Oregon nontuberculous mycobacteria (NTM) cohort; immune correlates of pulmonary NTM disease progression
19) The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
20) Clinical Utility of Extracellular RNA for Biomarker Development (UH2/UH3)
21) Functional and Structural Optical Coherence Tomography for Glaucoma
22) A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
23) VAPORHCS/OHSU J: Identifying the Determinants of Long-Term Type Specific Immunity in a Dengue Immune Cohort (VA#3596)
24) CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia (CASCADE FH Registry)
25) The immunogenicity and safety of Zostavax® and Shingrix® in rheumatoid arthritis patients using abatacept
26) Optical coherence tomography angiography in neovascular age-related macular degeneration
27) A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
28) War on Melanoma: Enlisting a cohort of melanoma survivors and their families
29) OCTRI Research Volunteer Registry
30) A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
31) Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
32) Alzheimer's Comprehensive Treatment Network of Oregon and Washington (ACTNOW)
33) Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
34) Long Term Follow-Up of Patients Exposed to Lentiviral- Based CAR T-Cell Therapy
35) Corrona Psoriasis Registry
36) Sarcoma Survivorship Registry
37) CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
38) A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
39) CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
40) Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease
41) INTense Exercise foR surviVAL among men with Metastatic Prostate Cancer (INTERVAL-GAP4): A Multicenter, Randomized, Controlled, Phase III Study
42) Understanding the Experience of Childhood Cancer and its Impact on the Family
43) [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
44) A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma
45) Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
46) Congenital Heart Surgeons’ Society Studies in Congenital Heart Disease
47) A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation, With a Substudy in Subjects With Relapsed or Refractory Myelodysplastic Syndrome and a Substudy in Subjects With Advanced Hematologic Malignancies With Organ Impairment
48) A Phase 1 Non-Randomized, Open-Label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies
49) Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta
50) A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN)
51) Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)
52) Improving the effectiveness of orally-dosed emergency contraceptives in obese women
53) A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
54) Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia
55) Phase 1b/2 Study of BI 836858 with Azacitidine in Previously Untreate AML Patients >60 Years With Unique Molecular Features
56) A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
57) Left Atrial Appendage Ligation with the LARIAT® Suture Delivery System as Adjunctive Therapy to Pulmonary Vein Isolation (PVI) for Persistent or Longstanding Persistent Atrial Fibrillation
58) Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate with Prednisone and Androgen Deprivation Therapy after Treatment with Docetaxel and Androgen Deprivation Therapy
59) Pyoderma Gangrenosum Study (PyGaS): Understanding the natural course, diagnosis, prognosis and outcomes
60) Wide-field and High-Resolution Optical Coherence Tomography Angiography in Diabetic Retinopathy
61) Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
62) A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy
63) A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with MLL gene rearrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)
64) A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
65) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
66) A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies
67) A phase 1B trial of preoperative eribulin and radiation for retroperitoneal liposarcoma
68) Transcatheter Aortic Valve Replacement to Unload the Left Ventricle in Patients with Advanced Heart Failure: A Randomized Trial (TAVR UNLOAD)
69) VHAPORHCS/OHSU J: STAT-PD: Preventing Levodopa Induced Dyskinesia in Parkinson's disease with HMG-CoA Reductase Inhibitors (MIRB # 3869)
70) [NCI CIRB] A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
71) A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia > Age 60 years
72) A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age > 60 years
73) A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
74) A Phase 1/1b/2a, 3-Part, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination with Venetoclax in Subjects with Relapsed or Refractory Hematologic Malignancies
75) A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
76) VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
77) CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
78) VAPORHCS/OHSU J: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
79) Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer
80) A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
81) A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
82) A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
83) Natural History Study of CEP290-Related Retinal Degeneration
84) VAPORHCS/OHSU J: Effect of Genotype on Resting State Connectivity during Methamphetamine Administration (VA#4221)
85) Exercising Together: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer
86) Effect of tetrahydrocannabinol (THC) on sleep in humans
87) A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Advanced Phase Myeloproliferative Neoplasms.
88) Phase 2 Study with Pevonedistat in combination with Azacitidine targeting NEDD8-activating enzyme (NAE) in TP53 Mutant Untreated Acute Myeloid Leukemia patients ≥ 60 years of age
89) VAPORHCS/OHSU J: Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast (VA#4141)
90) Peptide Biomarkers for Alzheimer Disease
91) Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
92) Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
93) An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
94) A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies
95) [NCI CIRB] A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
96) A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
97) A novel therapeutic intervention to restore health and functioning in persons with chemotherapy-induced peripheral neuropathy
98) [NCI CIRB] S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
99) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
100) Phase 2 Study of AG-120 combined with Azacitidine in Previously Untreated AML Patients > 60 Years with an IDH1 Mutation
101) MODERATE – Monitoring dementia-related agitation using technology evaluation
102) VAPORHCS/OHSU J: Validation of Walking Aid Use Metrics in People with Multiple Sclerosis Using an Innovative, New Device: HoldTrak
103) A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
104) [WCG IRB - IAA] Gilteritinib Monotherapy or in Combination with Decitabine in Elderly Untreated FLT3 mutated Acute Myeloid Leukemia With High and Low Variant Allele Frequency (VAF) (Group 1) OR Gilteritinib in Combination with Decitabine and Venetoclax in Untreated FLT3 mutated Acute Myeloid Leukemia age ≥18 years or older With High and Low Variant Allele Frequency (VAF) (Group 2)
105) Body and the Brain: Interoception and Cortical Reactivity
106) Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System
107) A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
108) Comparison of two- versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
109) A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
110) Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
111) A Phase II study of Xisomab 3G3, a monoclonal antibody preventing the activation of FXI by FXIIa, for the prophylaxis of catheter-associated thrombosis.
112) A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
113) VAPORHC/OHSU J: Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis (MIRB#4069)
114) VAPORHCS/OHSU J: HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function (VA#3967)
115) [NCI CIRB] EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
116) [NCI CIRB] S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
117) A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
118) [NCI CIRB] A041501 - A Phase III Trial To Evaluate the Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
119) A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
120) A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer
121) [MCW IRB-CML MOU] Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients who Relapsed After a Prior Attempt at TKI Discontinuation
122) A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
123) Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) therapy and control sub groups: combination of Mitoxantrone, Etoposide and Cytarabine (MEC) and combination of Fludarabine, Cytarabine, and Filgrastim (FLAG) in Older Patients (≥ 50 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)
124) An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate
125) A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
126) VAPORHCS/OHSU J: Improving sleep, sleep-related outcomes, and biomarkers in Veterans (VA#4268)
127) [NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
128) Differentiating High Myopia from Glaucoma Using Functional and Structural Optical Coherence Tomography
129) A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
130) A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
131) A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
132) Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (triFluridine/tIpiracil) with ConcurrEnt Radiation in Previously Untreated Resectable Stage II and Stage III ReCtal CancEr (FIERCE)
133) [NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
134) An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis
135) [NCI CIRB] EA9161 - A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
136) A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
137) A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)
139) [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
140) A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 with Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
141) A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
143) [Copernicus Group - IAA] A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s Disease
144) Long-Term Follow Up Protocol for Subjects Treated with Gene-Modified T Cells
145) [NMDP - BMT CTN MOU] 1702: Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
146) [VUMC - IREx] The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea (LOFT-HF)
147) A Phase 1, Multicenter, Open-Label, Dose Finding Study of CC 99712, A BCMA Antibody-Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma
148) [NMDP - BMT CTN MOU] CTN 1704: Composite Health Assessment Model for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)
149) A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
150) Disabled Nursing Faculty Study
151) [NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
152) [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
153) [NCI CIRB] - EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
154) A Multicenter, Phase 1, open-label study of the FGFR inhibitor pemigatinib (INCB054828) administered after chemotherapy in newly diagnosed Acute Myeloid Leukemia (AML) with adverse or intermediate risk cytogenetics
155) A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.
156) [NCI CIRB] EA2165 - A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
157) Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
158) Evaluating the effects of resistance and aerobic exercise on glucose and lipids in pregnant women with gestational diabetes
159) [Advarra - SMART IRB] A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease
160) A First-in-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects with Autosomal Dominant Retinitis Pigmentosa (adRP) due to the P23H Mutation in the RHO Gene
161) A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
162) VAPORHCS/OHSU J: A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People with MS (MIRB#4317)
163) (BCH IRB) Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT)
164) A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS
165) [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
167) ORCASTRAIT Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology
168) [Advarra - IAA] A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
169) Cerebellar transcranial magnetic stimulation for motor control in progressive supranuclear palsy
170) Cerebrospinal Fluid Dynamics in Older Adults with and without Mild Cognitive Impairment
171) [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
172) Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
173) Assessing Cardiovascular Health Risk in Grandfamilies
175) A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
176) VAPORHCS/OHSU J: A randomized, open-label, multicenter, Phase 2b study to evaluate physical function, including balance and daily activity, in participants with castration-resistant prostate cancer treated with darolutamide or enzalutamide (Bayer 20609)
178) A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
179) A Phase 1b trial of CPX-351 Lower Intensity Therapy (LIT) plus Venetoclax as First Line Treatment for Subjects with AML who are Unfit for Intensive Chemotherapy
180) Disparities and Barriers to Care for Gender Non-conforming Patients with Epilepsy and Spells: A longitudinal study - PSU MOU- Build Exito
181) [Fred Hutch – SMART IRB]: Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogenic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Disease
182) An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)
183) A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
184) A Phase 1, Multicenter, Open-Label Study of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
185) Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized clinical trial of curcumin
186) A Phase 1/2, open-label, dose escalation and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer
187) [NCI CIRB] EA4181 - A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
188) Characteristics Associated with Communicative Participation after Total Laryngectomy
189) A Multicenter Phase Ib Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells
190) A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)
191) A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
192) MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
193) A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma
194) A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High-Risk, Newly Diagnosed Multiple Myeloma (KarMMA-4)
195) [WCG IRB - IAA] A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
196) Cannabidiol and Oral Contraceptive Pills: Exploring a Substance-Drug Interaction
197) [NCI CIRB] A051701 - Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
198) [Advarra - IAA] - TRC-PAD Program: In-Clinic Trial-Ready Cohort for the Prevention of Alzheimer's Disease - Protocol ATRI-004
199) A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma - Expansion Cohort Segment Only
200) A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis
201) An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
202) Phase II randomized multi-center trial of total neoadjuvant therapy with and without CD40 agonist, APX005M, for locally advanced rectal adenocarcinoma
203) An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males with X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
204) VAPORHCS/OHSU J: Retinal microvasculature as a predictor of neurodegeneration in multiple sclerosis (VA#4478)
205) An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients with Hematological Malignancies
206) [University of Oregon IRB - IAA] Enhancing Health and Quality of Life for Individuals with Dementia Through Transitional-State Snacks
207) [WCG IRB- IAA] Phase 1b/2 Study of AZD5153 Combined with Venetoclax in Relapsed/Refractory (Phase 1b) and Previously Untreated AML Patients (Phase 2)
208) [WCG IRB- IAA] Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥ Age 60 years
209) A phase 1 study of SGN-CD228A in select advanced solid tumors
210) A Phase 1B, Multi-center, Open-label Study to determine the Safety, Pharmacokinetics, and Preliminary Efficacy of CC-99282 in combination with Obinutuzumab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
211) Nutritional stimulation of muscle protein synthesis and metabolic rate after bariatric surgery
212) Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
213) A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
214) OHSU IIT: A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer
215) Microbiome and Esophageal Cancer Progression (MEP) Study
216) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
217) (Advarra IRB IAA) A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1) Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
218) VAPORHCS/OHSU J: Supplemental Amino Acid Rehabilitative Therapy in TBI (VA#4413)
219) Understanding the Experience of Adolescent and Young Adult Cancer (AYA Cancer Study)
220) (Advarra-IRB) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
221) Human Blood Collection From Healthy HIV-Negative And HIV-Infected Donors.
222) A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
223) Understanding the Experience of Opioid Use Disorder (OUD Study)
224) A Phase 1/2 Study of RTX-240 as a Monotherapy and in Combination with Pembrolizumab
225) PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer
226) A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
227) EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
228) Sleep duration and cardiovascular health
229) Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release.
230) A Phase 1A/B Study to Evaluate the Safety and Tolerability of JSP191 in Combination with a Conditioning Regimen of Low Dose Radiation and Fludarabine in Subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT).
231) University of Pittsburgh - SMART IRB LOA: Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
232) A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
233) A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
234) VAPORHCS/OHSU J: A Pilot Study on the Coagulopathy of COVID-19: Comparison of Thrombotic Risks and Outcomes of Patients with and without Cardiovascular Disease (CVD) & SARS-CoV2/COVID-19 (VA#4625)
235) NeoOPTIMIZE: an open-label, phase II trial to assess the efficacy of adaptive switching of modified FOLFIRINOX or Gemcitabine/nab-Paclitaxel as a neoadjuvant strategy for patients with resectable and borderline resectable/ locally advanced unresectable pancreatic cancer.
236) BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
237) [NCI CIRB] NCICOVID - NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
238) Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR-105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
239) ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome
240) A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy
241) [NCI CIRB] EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
242) VAPORHCS/OHSU J: Firearm Injuries among Rural Veterans in the U.S.: Development of a DIPEx Module (VA#4728)
243) [WIRB - IAA] The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort
244) A Single Arm Phase II Study of Isatuximab with Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple Myeloma
245) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
246) [JHU SOM - IREx] A Sequenced Strategy for Improving Outcomes in Patients with Knee Osteoarthritis Pain (SKOAP)
247) Real World Observational Study using clonoSEQ Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
248) An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
249) A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
250) An assessor-blinded, randomized, controlled, single center, parallel design trial with patient masking to compare early postoperative gastric emptying associated with rocuronium neuromuscular reversal with sugammadex versus neostigmine in adults undergoing colon and rectal surgery.
251) [Advarra-IAA] FoxBioNet: ECV (Extracellular Vesicle) 004
252) A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
253) A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
254) A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin
255) A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
256) Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
257) A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure
258) Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness
259) Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma
260) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis (R668-AD-1924)
261) A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)
262) [WIRB - IAA] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
263) A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
264) A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis
265) A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
266) SARC038: A Phase 2 Study of Regorafenib in Combination with Nivolumab in Patients with Refractory or Recurrent Osteosarcoma
267) [NCI CIRB] S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
268) The Breast Cancer Observational Study
269) PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
270) A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)
271) The Gastrointestinal Cancer Observational Study (GICOS)
272) [NCI CIRB] EA2182 - A Randomized Phase II Study of De-Intensified ChemoRadiation for EarlyStage Anal Squamous Cell Carcinoma (DECREASE)
273) [NCI CIRB] S1933 - A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
274) A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
275) A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancerr
276) Establishing a ctDNA biomarker to improve organ preserving strategies in patients with rectal cancer
278) Prazosin for Disruptive Agitation in Alzheimer’s Disease (AD) (PEACE-AD)
279) WCG-IRB Using Technology to Support Care Partners for Persons with Alzheimer's Disease: Tele-STELLA
280) A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, Estrogen Receptor Positive, HER2-negative Breast Cancer (DARE)
281) Ability of the human gut microbiome to induce phenotypes related to the central and enteric nervous system in germ-free mice
284) [NCI CIRB] EA2176 - A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
285) A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis (ARQ-151-311)
286) [NCI CIRB] EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation
287) [NCI CIRB] A041703: A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
289) CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
290) Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL
291) Skin Fluorescent Imaging (SFI) System in Patients with Nevi (Orlucent SFI003)
292) Impact of SARS-CoV-2 infection and vaccination against COVID-19 on maternal and fetal immune outcomes
294) [NCI CIRB] S1900E - A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
295) Electrophysiologic Study of Acupuncture's Temporal Effect on Nociception in Chronic Low Back Pain Patients
296) Telehealth Delivery of Joint Attention Symbolic Play Engagement and Regulation Enhanced Milieu teaching with Caregivers of Newly Diagnosed Toddlers with ASD
297) A Phase 2, Subprotocol of DAY101 Monotherapy for Patients with Recurrent, Progressive, or Refractory Solid Tumors with MAPK Pathway Aberrations
298) [NCI CIRB] EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
299) Project Danube: Multi-Cancer and Comorbidity Blood Sample Collection for Cross-Reactivity Analysis for a Multiomics CRC Screening Test
300) [NCI CIRB] EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
301) A Brief Mindfulness Meditation Intervention for Physiological Stress Reactivity and Recovery Among Veterans with PTSD
302) Models for aging and Alzheimer with image-based cerebrovascular network synthesis (iCNS)
303) A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
304) [WCG IRB - IAA] A Phase 1b Study of AZD5991 + Azacitidine (AZA) in previously untreated patients ≥60 years with hypermethylation and marker Negative AML
305) VAPORHCS/OHSU J: Enhanced environments for psychophysical evaluation and training (VA#4346)
306) Feasibility of substitution of virtual reality greenspace and volatile organic compound humidification to simulate the forest experience effects on immune system recovery.
307) [NCI CIRB] EA8191 - Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
308) A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
309) [NMDP IRB-MOU] Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
310) [NUNM - IAA] Xanthohumol Microbiome and Signature in Crohn’s Disease (XMaS in Crohn’s) Trial
311) [NCI CIRB] NRG-BR007 - A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score less than or equal to 18 Breast Cancer
312) [Advarra - IAA] Trio analysis of Recurrent pregnancy loss Integrated bioinformatics genOmics Study (TRIOS)
313) Diagnosis of Heavy Menstrual Bleeding Using Alternative Period Products
314) The role of PAI-1, tPA, TFPI and endometrial endothelial cells in uterine hemostasis in humans
315) [NCI CIRB] S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Return to Search